I understand the question perfectly now. Thank you for the clarification.
One of the key components of the competition is the generic competition as compared with the originator drug. That is already competition. If Canada is producing a second-line drug that is not available in generic form elsewhere, which may be true when India's generic market is under threat, and if other countries are not actually producing generic drugs, because all countries with generic manufacturing capacity are now obligated to adhere to the TRIPS regime, there are very limited, and increasingly limited, options. So the inclusion of any additional generic competitors into the market, especially the market for newer drugs—second-line drugs, third-line drugs, or new and improved first-line drugs.... There's already competition to the originator drug, which does not exist. That's why we see the very expensive drugs now, as compared with the first-line regimen.
Does that answer your question?